236 related articles for article (PubMed ID: 24072883)
21. Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.
Ponnurangam S; Standing D; Rangarajan P; Subramaniam D
Mol Cancer Ther; 2013 May; 12(5):598-609. PubMed ID: 23427297
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activator inhibitor-1 in cancer research.
Li S; Wei X; He J; Tian X; Yuan S; Sun L
Biomed Pharmacother; 2018 Sep; 105():83-94. PubMed ID: 29852393
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.
Stefansson S; McMahon GA; Petitclerc E; Lawrence DA
Curr Pharm Des; 2003; 9(19):1545-64. PubMed ID: 12871067
[TBL] [Abstract][Full Text] [Related]
24. Functional relevance of D,L-sulforaphane-mediated induction of vimentin and plasminogen activator inhibitor-1 in human prostate cancer cells.
Vyas AR; Singh SV
Eur J Nutr; 2014 Apr; 53(3):843-52. PubMed ID: 24092501
[TBL] [Abstract][Full Text] [Related]
25. Linoleic acid enhances angiogenesis through suppression of angiostatin induced by plasminogen activator inhibitor 1.
Nishioka N; Matsuoka T; Yashiro M; Hirakawa K; Olden K; Roberts JD
Br J Cancer; 2011 Nov; 105(11):1750-8. PubMed ID: 22015554
[TBL] [Abstract][Full Text] [Related]
26. The urokinase plasminogen activator system: role in malignancy.
Duffy MJ
Curr Pharm Des; 2004; 10(1):39-49. PubMed ID: 14754404
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis.
Balsara RD; Ploplis VA
Thromb Haemost; 2008 Dec; 100(6):1029-36. PubMed ID: 19132226
[TBL] [Abstract][Full Text] [Related]
28. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
[TBL] [Abstract][Full Text] [Related]
29. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.
Bajou K; Peng H; Laug WE; Maillard C; Noel A; Foidart JM; Martial JA; DeClerck YA
Cancer Cell; 2008 Oct; 14(4):324-34. PubMed ID: 18835034
[TBL] [Abstract][Full Text] [Related]
30. Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.
Placencio VR; Ichimura A; Miyata T; DeClerck YA
PLoS One; 2015; 10(7):e0133786. PubMed ID: 26207899
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling.
Ma Q; Chen W; Chen W
Tumour Biol; 2016 May; 37(5):6107-16. PubMed ID: 26611645
[TBL] [Abstract][Full Text] [Related]
32. Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects.
Jing Y; Kovacs K; Kurisetty V; Jiang Z; Tsinoremas N; Merchan JR
Mol Cancer Res; 2012 Oct; 10(10):1271-81. PubMed ID: 22912336
[TBL] [Abstract][Full Text] [Related]
33. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
[TBL] [Abstract][Full Text] [Related]
34. Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.
Ceci C; Tentori L; Atzori MG; Lacal PM; Bonanno E; Scimeca M; Cicconi R; Mattei M; de Martino MG; Vespasiani G; Miano R; Graziani G
Nutrients; 2016 Nov; 8(11):. PubMed ID: 27879653
[TBL] [Abstract][Full Text] [Related]
35. Tiplaxtinin impairs nutritionally induced obesity in mice.
Lijnen HR; Alessi MC; Frederix L; Collen D; Juhan-Vague I
Thromb Haemost; 2006 Dec; 96(6):731-7. PubMed ID: 17139366
[TBL] [Abstract][Full Text] [Related]
36. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
37. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
38. XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro.
Brooks TD; Wang SW; Brünner N; Charlton PA
Anticancer Drugs; 2004 Jan; 15(1):37-44. PubMed ID: 15090742
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
40. A Novel Long Non-Coding RNA KMU15 Promotes Growth and Chemoresistance of Bladder Cancer.
Huang Y; Luan T; Bao X; Fu S; Li N; Li H; Wang H; Li C; Wang J
Clin Lab; 2019 Dec; 65(12):. PubMed ID: 31850704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
